Guardant360 test detects DNA segments in the patient's blood, originated from the cancerous tumor or its metastasis
Representational Image
Guardant360 test detects DNA segments in the patient's blood, originated from the cancerous tumor or its metastasis.
After examining 116 advanced stage non-small-cell lung carcinoma cancer patients, the study concluded that 65 percent of the patients had a genetic modification that could be treated with drugs approved by the US Food and Drug Administration.
Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates
